Nicotine metabolism and urinary elimination in mouse: In vitro and in vivo

Xenobiotica

Volumn 38, Issue 1, 2008, Pages 34-47

  Raunio, H ^a   Pokela, N ^a   Puhakainen, K ^a   Rahnasto, M ^a   Mauriala, T ^a   Auriola, S ^a   Juvonen, R O ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

CYP2A5; Human mouse correlation; Nicotine oxidation

Indexed keywords

3 HYDROXYCOTINE; COTINE N OXIDE; COTININE; CYTOCHROME P450 2A5; CYTOCHROME P450 INHIBITOR; ENZYME ANTIBODY; METHOXSALEN; NICOTINE; NICOTINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME METABOLISM; METABOLITE; MOUSE; NONHUMAN; OXIDATION; PROTEIN FUNCTION; URINARY EXCRETION; XENOBIOTIC METABOLISM;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; KINETICS; MICE; MICE, INBRED DBA; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NICOTINE; OXIDATION-REDUCTION;

MUS;

EID: 37549042058     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701708539     Document Type: Article

References (40)

1. Asikainen A, Tarhanen J, Poso A, Pasanen M, Alhava E, Juvonen RO. 2003. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicology In Vitro 17:449-455.
2. Benowitz NL. 1996, Pharmacology of nicotine: Addiction and therapeutics. Annual Review of Pharmacology and Toxicology 36:597-613.
3. Brandange S, Lindblom L. 1979. The enzyme 'aldehyde oxidase' is an iminium oxidase. Reaction with nicotine delta 10(50) iminium ion. Biochemical and Biophysical Research Communications 91:991-996.
4. Damaj MI, Siu EC, Sellers EM, Tyndale RF, Martin BR. 2007. Inhibition of nicotine metabolism by methoxsalen: Pharmacokinetic and pharmacological studies in mice. Journal of Pharmacology and Experimental Therapeutics 320:250-257.
5. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ. 2003. Comparative Risk Assessment Collaborating Group. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 362:271-280.
6. Frieling H, Bleich S. 2006. Tranylcypromine: New perspectives on an 'old' drug. European Archives of Psychiatry and Clinical Neuroscience 256:268-273.
7. George TP, O'Malley SS. 2004. Current pharmacological treatments for nicotine dependence. Trends in Pharmacological Sciences 25:42-48.
8. Honkakoski P, Negishi M. 1997. The structure, function and regulation of cytochrome P450 2A enzymes. Drug Metabolism Reviews 29:977-996.
9. Hukkanen J, Jacob P, Benowitz NL. 2005. Metabolism and disposition kinetics of nicotine. Pharmacological Reviews 57:79-115.
10. Juvonen RO, Gynther J, Pasanen M, Alhava E. 2000. Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases. Xenobiotica 1:81-92.
11. Juvonen RO, Kaipainen PK, Lang MA. 1985. Selective induction of coumarin 7-hydroxylase by pyrazole in D2 mice. European Journal of Biochemistry 152:3-8.
12. Kamataki T, Fujieda M, Kiyotani K, Iwano S, Kunitoh H. 2005. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. Biochemical and Biophysical Research Communications 338:306-310.
13. Lang MA, Gielen JE, Nebert DW. 1981. Genetic evidence for many unique liver microsomal P-450 mediated monooxygenase activities in heterogenic stock mice. Journal of Biological Chemistry 256:12068-12075.
14. Mäenpää J, Juvonen R, Raunio H, Rautio A, Pelkonen O. 1994. Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochemical Pharmacology 48:1363-1369.
15. Mäenpää J, Sigusch H, Raunio H, Syngelmä T, Vuorela P, Vuorela H, Pelkonen O. 1993. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochemical Pharmacology 45:1035-1042.
16. Malaiyandi V, Sellers EM, Tyndale RF. 2005. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clinical Pharmacology and Therapeutics 77:145-158.
17. McNeely W, Goa KL. 1998. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs 56:667-690.
18. Messina ES, Tyndale RF, Sellers EM. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 282:1608-1614.
19. Murphy SE, Raulinaitis V, Brown KM. 2005. Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metabolism and Disposition 33:1188-1173.
20. Nakajima M, Yamamoto T, Nunoy K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. 1996. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. Journal of Pharmacology and Experimental Therapy 277:1010-1015.
21. Oscarson M. 2001. Genetic polymorphism in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism. Drug Metabolism and Disposition 29:91-95.
22. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. 1998. Inhibition and induction of human P450 (CYP) enzymes. Xenobiotica 28:1203-1253.
23. Pelkonen O, Rautio A, Raunio H, Pasanen M. 2000. CYP2A6: A human coumarin 7-hydroxylase. Toxicology 144:139-147.
24. Poso A, Gynther J, Juvonen RO. 2001. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors. Journal of Computer Aided Molecular Design 15:195-202.
25. Poso A, Juvonen R, Gynther J. 1995, Comparative molecular field analysis of compounds with CYP2A5 binding affinity. Quantitative Structure-Activity Relationship 14:507-511.
26. Rahnasto M, Raunio H, Poso A, Juvonen R. 2003. More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde. Xenobiotica 33:529-539.
27. Rahnasto M, Raunio H, Poso A, Wittekindt C, Juvonen RO. 2005. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. Journal of Medicinal Chemistry 48:440-449.
28. Raunio H, Juvonen R, Pasanen M, Pelkonen O, Pääkkö P, Soini Y. 1998. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 27:427-432.
29. Raunio H, Rautio A, Gullsten H, Pelkonen O. 2001. Polymorphisms of CYP2A6 and its practical consequences. British Journal of Clinical Pharmacology 52:357-363.
30. Sellers EM, Kaplan HL, Tyndale RF. 2000. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology and Therapeutics 68:35-43.
31. Sellers EM, Tyndale RF. 2000. Mimicking gene defects to treat drug dependence. Annals of the New York Academy of Sciences 909:233-246.
32. Sellers EM, Tyndale RF, Fernandes LC. 2003. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discovery Today 8:487-493.
33. Siu ECK, Tyndale RF. 2007. Characterization and comparison of nicotine and cotinine metabolism in vitro and in vitro in DBA/2 and C57BL/6 mice. Molecular Pharmacology 71:826-834.
34. Siu ECK, Wildenauer DB, Tyndale RF. 2006. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology 184:401-408.
35. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. 1985. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 150:76-85.
36. Su T, Ding X. 2004. Regulation of the cytochrome P450 2A genes. Toxicology and Applied Pharmacology 199:285-294.
37. Taavitsainen P, Juvonen R, Pelkonen O. 2001. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, tranyl-2phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metabolism and Disposition 29:217-222.
38. Tyndale RF, Sellers EM. 2001. Variable CYP2A6-mediated metabolism alters smoking behaviour and risk. Drug Metabolism and Disposition 29:548-552.
39. Wood AW, Conney AH. 1974. Genetic variation in coumarin hydroxylase activity in the mouse (Mus musculus). Science 185:612-614.
40. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. 2001. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism and Disposition 29:897-902.